TIDMMXCT TIDMTTM
RNS Number : 4604H
MaxCyte, Inc.
03 August 2021
MaxCyte Announces Closing of Offering and Resulting Total Voting
Rights
This announcement contains inside information
GAITHERSBURG, MD, August 3, 2021 - MaxCyte, Inc., (NASDAQ: MXCT)
(LSE: MXCT, MXCN) ("MaxCyte" or the "Company"), a leading provider
of cell-engineering platform technologies, today announced the
closing of its offering of 15,525,000 shares of common stock (the
"Offering") at a price of US $13.00 per share, for aggregate gross
proceeds of approximately US $201,825,000, before deducting
underwriting discounts and commissions and estimated offering
expenses payable by MaxCyte. The shares of common stock were
offered in a registered public offering in the United States.
MaxCyte's common stock began trading on the Nasdaq Global Select
Market under the symbol "MXCT" on July 30, 2021. MaxCyte's common
stock will continue to be admitted to trading on the AIM market of
London Stock Exchange plc ("AIM") under the symbols "MXCT" and
"MXCN." Application has been made for the shares of common stock
issued in the Offering to be admitted to trading on AIM and it is
expected that admission will become effective and dealings in the
shares of common stock will commence at 8:00 a.m. (BST) on 4
August, 2021.
Cowen, Stifel and William Blair acted as joint book-running
managers for the Offering and as representatives of the
underwriters for the Offering. BTIG and Stephens Inc. acted as
co-managers of the Offering.
Following the closing of the Offering, the issued share capital
of the Company is 100,259,803 shares of common stock, including the
shares issued in the Offering and 15,458 shares issued in July 2021
pursuant to the exercise of options. This figure may be used by
shareholders as a denominator for the calculations by which they
will determine if they are required to notify their interest in, or
change to their interest in, the Company, under the applicable
Securities and Exchange Commission disclosure rules or under the
Disclosure Guidance and Transparency Rules published by the
Financial Conduct Authority. The number of unrestricted shares of
common stock trading under the symbol "MXCT" is 99,929,803 and the
number of restricted shares of common stock trading under the
symbol "MXCN" is 330,000.
A registration statement, including a prospectus, relating to
these securities has been filed by MaxCyte and was declared
effective by the Securities and Exchange Commission on 29 July
2021. Copies of the registration statement can be accessed through
the SEC's website at www.sec.gov. The Offering was made only by
means of a prospectus. Copies of the final prospectus relating to
and describing the terms of the Offering may be obtained from the
offices of Cowen and Company, LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, USA,
Attn: Prospectus Department, by telephone at +1 (833) 297-2926 or
by email at PostSaleManualRequests@broadridge.com; Stifel, Nicolaus
& Company, Incorporated, Attention: Prospectus Department, One
Montgomery Street, Suite 3700, San Francisco, CA 94104, USA, by
telephone at +1 (415) 364-2720 or by email at
syndprospectus@stifel.com; or William Blair & Company, L.L.C.,
Attention: Prospectus Department, 150 North Riverside Plaza,
Chicago, IL 60606, USA, by telephone at +1 (800) 621-0687 or by
email at prospectus@williamblair.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities law of any such
state or jurisdiction.
About MaxCyte
MaxCyte is a leading provider of cell-engineering platform
technologies to advance innovative cell-based research, development
and potential commercialisation of next-generation cell therapies.
The company's existing customer base ranges from large
biopharmaceutical companies -- including 20 of the top 25
pharmaceutical companies based on 2020 global revenue -- to
hundreds of biotechnology companies and academic translational
centers. MaxCyte has granted 13 strategic platform licences to
commercial cell therapy developers that allow for more than 75
clinical programmes. Founded in 1998, MaxCyte is headquartered in
Gaithersburg, Maryland, US.
MaxCyte Contacts:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer +1 301-944-1660
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black / Duncan Monteith / Matthew O'Dowd +44 (0)20 7260 1000
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison / Samira Essebiyea
Corporate Broking
Nick Adams +44 (0)20 7710 7600
UK IR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
US IR Adviser
Gilmartin Group +1 415-937-5400
David Deuchler, CFA ir@maxcyte.com
Forward-Looking Statements
Certain statements made in this press release are
forward-looking statements including with respect to the admission
of the shares of common stock to trading on AIM. These
forward-looking statements are not historical facts but rather are
based on the Company's current expectations, estimates, and
projections about its industry; its beliefs; and assumptions. Words
such as "anticipates," "expects," "intends," "plans," "believes,"
"seeks," "estimates" and similar expressions are intended to
identify forward-looking statements. These statements are not
guarantees of future performance and are subject to known and
unknown risks, uncertainties, and other factors, some of which are
beyond the Company's control, are difficult to predict, and could
cause actual results to differ materially from those expressed or
forecasted in the forward-looking statements, including if the
shares of common stock are not admitted to trading on AIM or
admission is delayed or if there are adverse market or economic
conditions. The Company cautions security holders and prospective
security holders not to place undue reliance on these
forward-looking statements, which reflect the view of the Company
only as of the date of this press release. The forward-looking
statements made in this press release relate only to events as of
the date on which the statements are made. The Company will not
undertake any obligation to release publicly any revisions or
updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDKNBQQBKDFFK
(END) Dow Jones Newswires
August 03, 2021 10:51 ET (14:51 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024